7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

76,058.01

-9.67

-0.01%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

ASX - Delayed Quote AUD

Radiopharm Theranostics Limited (RAD.AX)

0.0040 +0.0010 (+33.33%)

At close: November 6 at 2:44:57 PM GMT+11

Loading Chart for RAD.AX

Chart Range Bar

Interval:

In partnership with ChartIQ

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

RADX: Fiscal 3Q:26 Cash Flow Report

RADX: Fiscal 3Q:26 Cash Flow Report

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks

Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks

Mobilize your Website

View Site in Mobile | Classic

Share by: